BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension

By afschroeder • August 30, 2025

Sahay S, Palevsky H, El-Kersh K, Restrepo-Jaramillo R, Bajwa AA, Desai S, Joly JM, Spikes LA, Eggert MS, Johri S, Shapiro SM, Fisher MR, Shah TG, Ramani GV, Mehta JP, Thrasher CM, Deng C, Smith P, Broderick M, Burger CD. BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension. Respir Med. 2025 Aug 27;248:108318. doi: 10.1016/j.rmed.2025.108318. Epub ahead of print. PMID: 40882760.

Tags: Cardiology/Epi, Dry powder inhaler, exercise capacity, Prostacyclin dosing, Publications, pulmonary arterial hypertension, Treprostinil, Veterans Administration

Nuclear mechanotransduction: tools for mechanical perturbation and chromatin characterization

Soto J, Origer N, Wu Y, Cardenas Benitez B, Massad R, Rahgoshay D, Lee A, Downing T, Li S. Nuclear mechanotransduction: tools for mechanical perturbation[...]

Cannabis Is Associated With Potentially Proatherogenic Inflammation in Youth

Kelesidis T, Fotooh Abadi L, Lama Tamang P, Hampilos K, Fong R, Sanchez J, Ruedisueli I, Gornbein J, Cooper ZD, Middlekauff HR. Cannabis Is Associated[...]

Clinical outcomes among individuals with systemic inflammation following myocardial infarction: Insights from the veterans affairs healthcare system

Sandhu AT, Furst A, Rodriguez F, Kalwani N, Maron DJ, Nallamshetty S, Din N, Fan M, Khachatourian K, Skaar JR, Tonnu-Mihara I. Clinical outcomes among[...]